Huadong Medicine | Sustainability Performance
Produces and distributes pharmaceutical products.
1993
China
10,001+ employees
Pharmaceuticals
$1B - 10B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#11156
Overallⓘ#840
in Chinaⓘ#265
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsEnergy consumptionWaste ManagementWater ManagementAir & land impactNature and biodiversitySocial
Diversity and InclusionPay GapsExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Laggard
Laggard
Critical
Critical
Intensity
Greenhouse gas intensity Scope 1, 2 (tCO₂e /$M)
Energy consumption (direct) intensity (MWh /$M)
Industry Benchmark
30.8
B/M 22.4
65.5
B/M 42.0
Powered by illuminem and GIST Impact
Controversy level
- Huadong Medicine Co Ltd, Chinese pharma, has faced sustained Chinese NMPA enforcement scrutiny over alleged inadequate disclosure of multiple drug product quality at Hangzhou production facilities, plus periodic Chinese SAMR enforcement on alleged misleading marketing of weight-loss product GLP-1 analogs affecting Chinese consumer protection.
